Nasdaq:CLNN

Primary endpoint of time to substantial symptom resolution was not met in acutely symptomatic, non-hospitalized COVID-19 patientsCNM-ZnAg treatment was safe and well-tolerated SALT LAKE CITY, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Clene…

CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating…